ArticleCancer letters2014
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.
Article in Cancer letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Nanoscale biointerfaces in inter-organelle communication: membrane contact sites, organelle trafficking, and cell fate control.Frontiers in cell and developmental biology · 2026Review
- Nanoplatform-Mediated Remodeling of the Immune Microenvironment in Renal Cell Carcinoma.International journal of nanomedicine · 2026Review
- Liposome-Loaded Mesenchymal Stem Cells Enhance Tumor Accumulation and Anti-Tumor Efficacy of Doxorubicin in Mouse Tumor Models of Melanoma.Pharmaceutics · 2025Article
- An Insight into Perfusion Anisotropy within Solid Murine Lung Cancer Tumors.Pharmaceutics · 2024Article
- Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer.Molecules (Basel, Switzerland) · 2024Review
- Current research trends of nanomedicines.Acta pharmaceutica Sinica. B · 2023Review
- Nanomedicine in cancer therapy.Signal transduction and targeted therapy · 2023Review
- Efficient Liposome Loading onto Surface of Mesenchymal Stem Cells via Electrostatic Interactions for Tumor-Targeted Drug Delivery.Biomedicines · 2023Article
- Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Progress and Hurdles of Therapeutic Nanosystems against Cancer.Pharmaceutics · 2022Review
- Roadmap on nanomedicine.Nanotechnology · 2021Article
- Photo-Responsive Supramolecular Micelles for Controlled Drug Release and Improved Chemotherapy.International journal of molecular sciences · 2020Article
- Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.Theranostics · 2020Review
- Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy.Translational oncology · 2019Article
- Clinical Cancer Nanomedicine.Nano today · 2019Article
- Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.Molecular imaging and biology · 2019Review
- Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.Drug delivery and translational research · 2018Review
- Therapeutic Peptide Amphiphile as a Drug Carrier with ATP-Triggered Release for Synergistic Effect, Improved Therapeutic Index, and Penetration of 3D Cancer Cell Spheroids.International journal of molecular sciences · 2018Article
- Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery.Theranostics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.